Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Journal of Human Hypertension

Volumn 17, Issue 6, 2003, Pages 425-432

  Chrysant, S G ^a   Marbury, T C ^b   Robinson, T D ^c  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

Amlodipine; Angiotensin II receptor blocker; Olmesartan medoxomil

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; OLMESARTAN; PLACEBO;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARALLEL DESIGN; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038042008     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001577     Document Type: Article

References (26)

1. Birkenhager WH, De Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999; 17: 873-881.
2. Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999; 10 (Suppl 12): S278-S282.
3. Neutel J. Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999; 84: 13K-17K.
4. Neutel J. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87 (Suppl): 37C-43C.
5. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 (Suppl 2): S24-S28.
6. Van Mieghem W. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension. J Hypertens 2001; 19 (Suppl 2): S152.
7. Oparil S et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-291.
8. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
9. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199-201.
10. Bakris GL et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 2000; 36: 646-661.
11. Osterloh I. The safety of amlodipine. Am Heart J 1989; 118: 1114-1119.
12. Frishman WH et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995; 35: 1060-1066.
13. Ekpo EB, Shah IU, Fernando MU, White AD. Isolated systolic hypertension in the elderly: Survey of practitioners' attitude and management. Gerontology 1993; 39: 207-214.
14. Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225: 101-105.
15. Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
16. Pitt B et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
17. Lindholm LH et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
18. Dahlöf B et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
19. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.
20. Kloner RA et al, for the Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 2001; 87: 727-731.
21. Lacourciere Y et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3: 295-302.
22. Corea L et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341-346.
23. Oparil S et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, vs amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18: 608-625.
24. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
25. Hebert LA et al, for the Modification of Diet in Renal Disease Study Group. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997; 30: 428-435.
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.